Novo Nordisk faces scrutiny for high Ozempic and Wegovy prices, retaining 60% of list price after rebates, with Senator Bernie Sanders urging price reduction.
Novo Nordisk faces scrutiny over its high prices for diabetes drug Ozempic and obesity drug Wegovy, retaining around 60% of the list price after rebates and fees paid to intermediaries in the U.S. healthcare system. The Danish drugmaker acknowledges the focus on list prices is misleading, as significant portions go to middlemen, and has expressed willingness to collaborate with lawmakers to address systemic issues hindering patient access. Senator Bernie Sanders has urged Novo to reduce prices, emphasizing the disparity between production costs and market prices.
May 28, 2024
8 Articles